| Weetalk Speech And Language Services, Llc | |
|
2851 Centre Ave, Reading, PA 19605-2567 | |
| (610) 750-6514 | |
| Not Available |
| Full Name | Weetalk Speech And Language Services, Llc |
|---|---|
| Type | Facility |
| Speciality | Early Intervention Provider Agency |
| Location | 2851 Centre Ave, Reading, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326190075 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Secondary |
| 252Y00000X | Early Intervention Provider Agency | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Weetalk Speech And Language Services, Llc 2851 Centre Ave, Reading, PA 19605-2567 Ph: (610) 750-6514 | Weetalk Speech And Language Services, Llc 2851 Centre Ave, Reading, PA 19605-2567 Ph: (610) 750-6514 |
News Archive
In their latest finding on the brain's role in controlling appetite and weight, researchers at the Albert Einstein College of Medicine have shown that reducing levels of fatty acids in the hypothalamus causes rats to overeat and become obese. Their results suggest that restoring fatty-acid levels in the brain may be a promising way to treat obesity.
The University of Pennsylvania's Alzheimer's Disease Core Center has been awarded an estimated $8.8 million over five years from the National Institute on Aging to continue its mission of investigating mechanisms, diagnostics, treatments and strategies for Alzheimer's Disease (AD) and related dementias including Parkinson's disease (PD), Parkinson's disease dementia (PDD), Lewy Body dementia (LBD) and frontotemporal lobar degeneration (FTLD).
Obesity surgery has proven to be just as effective for teenagers as for adults. Five years on, those who underwent the procedure as teenagers weighed, on average, 28 percent less than prior to the surgery.
Affymetrix, Inc. and Signature Diagnostics AG today announced that they have signed a Powered by Affymetrix™ (PbA) agreement. Under the agreement, Signature Dx obtains a worldwide license to use Affymetrix® microarray technology to develop and commercialize diagnostic and prognostic colorectal cancer (CRC) tests.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced updated results from a phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen.
› Verified 3 days ago